Why Intellia Therapeutics, Inc. (NTLA) Outpaced the Stock Market TodayZacks Investment Research • 05/03/24
Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2024 Earnings and Company UpdatesGlobeNewsWire • 05/02/24
3 Gene Editing Stocks with the Potential to Make You an Overnight MillionaireInvestorPlace • 05/02/24
Intellia Therapeutics to Present Updated Data from Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Congress 2024GlobeNewsWire • 04/29/24
Intellia (NTLA) Begins Dosing in Phase III ATTR Amyloidosis StudyZacks Investment Research • 03/19/24
Intellia Therapeutics Announces First Patient Dosed in the Phase 3 MAGNITUDE Study of NTLA-2001 as a Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with CardiomyopathyGlobeNewsWire • 03/18/24
Intellia Therapeutics Stock Has 119% Upside, According to 1 Wall Street AnalystThe Motley Fool • 03/06/24
Intellia Therapeutics, Inc. (NTLA) Crossed Above the 50-Day Moving Average: What That Means for InvestorsZacks Investment Research • 02/28/24
Intellia Therapeutics, Inc. (NTLA) Just Overtook the 20-Day Moving AverageZacks Investment Research • 02/27/24
Wall Street Analysts See an 185.54% Upside in Intellia Therapeutics, Inc. (NTLA): Can the Stock Really Move This High?Zacks Investment Research • 02/23/24
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Company ProgressGlobeNewsWire • 02/22/24
Biotech/Drug Stocks Q4 Earnings Due Feb 22: MRNA, BHC, NTLA, BMRN & MoreZacks Investment Research • 02/21/24